Overview

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kadmon Corporation, LLC
Treatments:
Erlotinib Hydrochloride
Gefitinib
XL647
Criteria
Inclusion Criteria:

- Histologically confirmed diagnosis of unresectable Stage IIIB or Stage IV relapsed or
recurrent NSCLC.

- Subjects must have:

1. documented (radiological or clinical) progressive disease (PD) following a prior
response (including stable disease) to monotherapy with erlotinib or gefitinib
that was administered for at least 12 weeks prior to progression OR

2. a documented T790M EGFR mutation

- Measurable disease defined according to RECIST

- ECOG performance status of 0 or 1.

- Sexually active subjects must use an accepted method of contraception during the
course of the study.

- Female subjects of childbearing potential must have a negative pregnancy test at
enrollment.

Exclusion Criteria:

- Received radiation to ≥25% of his or her bone marrow within 30 days of XL647
treatment.

- Received erlotinib or gefitinib, or other anticancer therapy within 14 days of the
first dose of study drug.

- Received an investigational drug (excluding erlotinib or gefitinib) within 30 days of
the first dose of study drug.

- Receiving anticoagulation therapy with warfarin.

- Not recovered to Grade ≤1 from adverse events (AEs) due to antineoplastic agents,
investigational drugs, or other medications that were administered prior to study
enrollment.

- Corrected QT interval (QTc) of >0.45 seconds.

- Progressive, symptomatic, or hemorrhagic brain or leptomeningeal metastases.

- Requires steroid or anticonvulsant therapy for the treatment of brain metastases.